Stem Cell Transplantation Therapy in Systemic Sclerosis:A Systematic Review
Keywords:
Stem Cell, Transplantation Therapy, Systemic SclerosisAbstract
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by systemic inflammation, tissue fibrosis, vascular dysfunction, and reduced quality of life. Autologous hematopoietic stem cell transplantation (HSCT) has been developed as a therapeutic option for severe SSc patients who do not respond to standard treatment. Objective: To evaluate the benefits and risks of autologous hematopoietic stem cell transplantation in the management of systemic sclerosis. Methods: A review was conducted on three randomized controlled trials (RCTs) comparing HSCT with cyclophosphamide use. Results: Selective non-myeloablative HSCT improved event-free survival and physical function, while selective myeloablative HSCT showed improvement in skin scores. However, both procedures carried a higher risk of severe adverse effects compared to cyclophosphamide. No significant differences in overall mortality were observed, and evidence on non-selective non-myeloablative HSCT remains limited. Conclusion: Although HSCT shows potential as a therapeutic option for SSc, the risks of severe adverse effects and mortality must be carefully considered. Further studies are needed to compare the effectiveness of HSCT with modern therapies, such as mycophenolate mofetil.
Downloads
References
1. Assassi S, Mayes MD, Pedroza C, Chang JT, Furst DE, CroBord LJ, et al. Immunoablation followed by autologous stem cell transplantation in systemic sclerosis patients decreases significantly the interferon signature. 2015 ACR/ARHP Annual Meeting; 6-11 Nov 2015; San Francisco (CA).
2. Assassi S, Wallace P, Ying J, Keyes-Elstein L, Goldmuntz E, Turner J. Treatment with myeloablation followed by autologous stem cell transplantation normalizes the systemic sclerosis molecular signature. Journal of Scleroderma and Related Disorders 2018;3:s272-3.
3. Assassi S, Wang X, Keyes-Elstein L, Goldmuntz E, Turner J, Zheng W. Changes in the systemic sclerosis molecular signatures aRer myeloablation followed by autologous hematopoietic stem cell transplantation and their clinical correlates. Arthritis and Rheumatology 2018;70(Suppl 9):s1002-3.
4. Bellocchi C, Ying J, Goldmuntz E, Keyes-Elstein L, Varga J, HinchcliB M, et al. Systemic sclerosis has a distinct serum protein profile that correlates with its clinical manifestations. Arthritis and Rheumatology 2018;70:s1213-4.
5. Bellochi C, Sullivan K, Goldmuntz E, Ying J, Keyes-Elstein L, Varga J, et al. Myeloablation followed by autologous stem cell rescue leads to normalisation of serum IL-6 levels in patients with systemic sclerosis. Annals of the Rheumatic Diseases 2018;77:s1100-1.
6. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantations compared with pulse cyclophosphamide once per months for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011;378:498-506.
7. Franks J, Martyanov V, Wood TA, CroBord L, Keyes-Elstein L, Furst DE. Machine learning classification of peripheral blood gene expression identifies a subset of patients with systemic sclerosis most likely to show clinical improvement in response to hematopoietic stem cell transplant. Arthritis and Rheumatology 2018;70:s2091-3.
8. Goldin J, Keyes-Elstein L, CroBord L, Furst DE, Goldmuntz E, Mayes MD, et al. Changes in quantitative scleroderma lung CT measures in patients treated with cyclophosphamide or transplantation. Arthritis and Rheumatology 2018;70:s1005-6. NCT00114530. Scleroderma: Cyclophosphamide Or Transplantation (SCOT). clinicaltrials.gov/ct2/show/ NCT00114530 (first received 16 June 2005). [NCT00114530]
9. Sullivan K, Keyes-Elstein L, McSweeney P, Pinckney A, Welch B, Mayes M, et al. Myeloablative autologous transplantation of CD34+ selected hematopoietic stem cells (HSCT) vs monthly intravenous cyclophosphamide (CY) for severe scleroderma with internal organ involvement: outcomes of a randomized North American clinical trial. Biology of Blood and Marrow Transplantation 2017;23:S118-91.
10. Sullivan K, Keyes-Elstein L, McSweeney P, Pinckney A, Welch B, Mayes MD, et al. Myeloablative autologous transplantation of CD34+-selected hematopoietic stem cells (HSCT) vs monthly intravenous cyclophosphamide (CYC) for severe scleroderma with internal organ involvement: outcomes of a randomized North American clinical trial [abstract]. Arthritis and Rheumatology 2016;68(Suppl 10):S21.
11. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. New England Journal of Medicine 2019;378:35-47. [PMID: 29298160]
12. Abdallah NA, Wang M, Lansiaux P, Puyade M, Berthier S, Terriou L, et al. Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score. Bone Marrow Transplantation 2021;56:2259-67.
13. van Laar JM, Farge D, Sont J, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diBuse cutaneous systemic sclerosis. JAMA 2014;311(24):2490-8.
14. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4: 708-19.
15. Keever-Taylor CA, Heimfeld S, Steinmiller KC, et al. Manufacture of autologous CD34+ selected grafts in the NIAIDsponsored HALT-MS and SCOT multicenter clinical trials for autoimmune diseases. Biol Blood Marrow Transplant 2017;23: 1463-72.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Arif Rachman, Shalya Regita, Muhammad Zhafran Maulana, Ni Made Ayu Widiyasih, Nabil Ramaseno, Nuzuludz Dzikra, Ilham Syahputro, Jafar Elyas, Dinda Puspa, Arya Duta Dharma, Arfiyanti Arfiyanti, Prihati Pujowaskito, Ruth Je Deborah Octavia (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
